Administration of lithium and magnesium chloride inhibited tolerance to the anticonvulsant effect of morphine on pentylenetetrazole-induced seizures in mice

Epilepsy and Behavior

Volumn 19, Issue 4, 2010, Pages 568-574

  Ghasemi, Abbas ^a,b   Saberi, Mohammad ^a,c   Ghasemi, Mehdi ^a,f   Shafaroodi, Hamed ^d   Moezi, Leila ^e   Bahremand, Arash ^a   Montaser Kouhsari, Laleh ^a   Ziai, Pouya ^a   Dehpour, Ahmad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

^e SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Lithium chloride; Magnesium chloride; Mice; Morphine; Opioid tolerance; Pentylenetetrazole; Seizure

Indexed keywords

LITHIUM CHLORIDE; MAGNESIUM CHLORIDE; MORPHINE; PENTETRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CLONIC SEIZURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERANCE; MALE; MOUSE; NONHUMAN;

ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG TOLERANCE; LITHIUM CHLORIDE; MAGNESIUM CHLORIDE; MALE; MICE; MORPHINE; PENTYLENETETRAZOLE; SEIZURES; TIME FACTORS;

EID: 78649940278     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2010.09.004     Document Type: Article

References (85)

1. Frenk H. Pro- and anticonvulsant actions of morphine and the endogenous opioids: involvement and interactions of multiple opiate and non-opiate systems. Brain Res 1983, 287:197-210.
2. Foote F., Gale K. Proconvulsant effect of morphine on seizures induced by pentylenetetrazol in the rat. Eur J Pharmacol 1984, 105:179-184.
3. Lauretti G.R., Ahmad I., Pleuvry B.J. The activity of opioid analgesics in seizure models utilizing N-methyl-dl-aspartic acid, kainic acid, bicuculline and pentylenetetrazole. Neuropharmacology 1994, 33:155-160.
4. Vaccarino A.L., Kastin A.J. Endogenous opiates: 1999. Peptides 2000, 21:1975-2034.
5. Longo V.G., Massotti M., Sagratella S. Convulsant drugs and changes in the electrical activity of the brain: an investigation of the effects of opioids on chemoconvulsions. Prog Clin Biol Res 1983, 124:121-127.
6. Homayoun H., Khavandgar S., Namiranian K., Gaskari S.A., Dehpour A.R. The role of nitric oxide in anticonvulsant and proconvulsant effects of morphine in mice. Epilepsy Res 2002, 48:33-41.
7. Berman E.F., Adler M.W. The anticonvulsant effect of opioids and opioid peptides against maximal electroshock seizures in rats. Neuropharmacology 1984, 23:367-371.
8. Puglisi-Allegra S., Cabib S., Oliverio A. Pharmacological evidence for a protective role of the endogenous opioid system on electroshock-induced seizures in the mouse. Neurosci Lett 1985, 62:241-247.
9. Frey H.H. Effect of mu- and kappa-opioid agonists on the electroconvulsive seizure threshold in mice and antagonism by naloxone and MR 2266. Pharmacol Toxicol 1988, 62:150-154.
10. Bajorek J.G., Lomax P. Modulation of spontaneous seizures in the mongolian gerbil: effects of beta-endorphin. Peptides 1982, 3:83-86.
11. Chen C.S., Gates G.R., Reynoldson J.A. Effect of morphine and naloxone on priming-induced audiogenic seizures in BALB/c mice. Br J Pharmacol 1976, 58:517-520.
12. Shavit Y., Caldecott-Hazard S., Liebeskind J.C. Activating endogenous opioid systems by electroconvulsive shock or footshock stress inhibits recurrent kindled seizures in rats. Brain Res 1984, 305:203-207.
13. Pavone F., Castellano C., Oliverio A. Strain-dependent effects of shock-induced release of opioids: dissociation between analgesia and behavioral seizures. Brain Res 1986, 366:326-328.
14. Tortella F.C., Long J.B., Holaday J.W. Endogenous opioid systems: physiological role in the self-limitation of seizures. Brain Res 1985, 332:174-178.
15. Tso P.H., Wong Y.H. Molecular basis of opioid dependence: role of signal regulation by G-proteins. Clin Exp Pharmacol Physiol 2003, 30:307-316.
16. Roshanpour M., Ghasemi M., Riazi K., Rafiei-Tabatabaei N., Ghahremani M.H., Dehpour A.R. Tolerance to the anticonvulsant effect of morphine in mice: blockage by ultra-low dose naltrexone. Epilepsy Res 2009, 83:261-264.
17. Prien R.F., Kupfer D.J., Mansky P.A., et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984, 41:1096-1104.
18. Nierenberg A.A. Treatment choice after one antidepressant fails: a survey of Northeastern psychiatrists. J Clin Psychiatry 1991, 52:383-385.
19. Nierenberg A.A., Cole J.O. Antidepressant adverse drug reactions. J Clin Psychiatry 1991, 52(Suppl.):40-47.
20. Jasinski D.R., Nutt J.G., Haertzen C.A., Griffith J.D., Bunney W.E. Lithium: effects on subjective functioning and morphine-induced euphoria. Science 1977, 195:582-584.
21. Abrahamson J.R. Use of lithium to control drug abuse. Am J Psychiatry 1983, 140:1256.
22. Dehpour A.R., Farsam H., Azizabadi-Farahani M. Inhibition of the morphine withdrawal syndrome and the development of physical dependence by lithium in mice. Neuropharmacology 1995, 34:115-121.
23. Liebman J.M., Segal D.S. Lithium differentially antagonises self-stimulation facilitated by morphine and (+)-amphetamine. Nature 1976, 260:161-163.
24. Dehpour A.R., Farsam H., Azizabadi-Farahani M. The effect of lithium on morphine-induced analgesia in mice. Gen Pharmacol 1994, 25:1635-1641.
25. Johnston I.N., Westbrook R.F. Inhibition of morphine analgesia by lithium: role of peripheral and central opioid receptors. Behav Brain Res 2004, 151:151-158.
26. Alborzi A., Mehr S.E., Rezania F., et al. The effect of lithium chloride on morphine-induced tolerance and dependence in isolated guinea pig ileum. Eur J Pharmacol 2006, 545:123-128.
27. Myracle A., Lopez-Grancha M., Flores P., Glowa J., Riley A.L. Differential effects of morphine and LiCl on schedule-induced polydipsia. Pharmacol Biochem Behav 2005, 80:195-202.
28. Begon S., Pickering G., Eschalier A., Dubray C. Magnesium increases morphine analgesic effect in different experimental models of pain. Anesthesiology 2002, 96:627-632.
29. Kroin J.S., McCarthy R.J., Von Roenn N., Schwab B., Tuman K.J., Ivankovich A.D. Magnesium sulfate potentiates morphine antinociception at the spinal level. Anesth Analg 2000, 90:913-917.
30. Ulugol A., Aslantas A., Ipci Y., Tuncer A., Hakan Karadag C., Dokmeci I. Combined systemic administration of morphine and magnesium sulfate attenuates pain-related behavior in mononeuropathic rats. Brain Res 2002, 943:101-104.
31. Farouk S., Aly A. A comparison of intra-articular magnesium and/or morphine with bupivacaine for postoperative analgesia after arthroscopic knee surgery. J Anesth 2009, 23:508-512.
32. Ghrab B.E., Maatoug M., Kallel N., et al. [Does combination of intrathecal magnesium sulfate and morphine improve postcaesarean section analgesia?]. Ann Fr Anesth Reanim 2009, 28:454-459.
33. Habibi-Asl B., Hassanzadeh K., Vafai H., Mohammadi S. Development of morphine induced tolerance and withdrawal symptoms is attenuated by lamotrigine and magnesium sulfate in mice. Pak J Biol Sci 2009, 12:798-803.
34. McCarthy R.J., Kroin J.S., Tuman K.J., Penn R.D., Ivankovich A.D. Antinociceptive potentiation and attenuation of tolerance by intrathecal co-infusion of magnesium sulfate and morphine in rats. Anesth Analg 1998, 86:830-836.
35. Shafaroodi H., Asadi S., Sadeghipour H., et al. Role of ATP-sensitive potassium channels in the biphasic effects of morphine on pentylenetetrazole-induced seizure threshold in mice. Epilepsy Res 2007, 75:63-69.
36. Bahremand A., Nasrabady S.E., Shafaroodi H., Ghasemi M., Dehpour A.R. Involvement of nitrergic system in the anticonvulsant effect of the cannabinoid CB1 agonist ACEA in the pentylenetetrazole-induced seizure in mice. Epilepsy Res 2009, 84:110-119.
37. Ghasemi M., Shafaroodi H., Nazarbeiki S., et al. Voltage-dependent calcium channel and NMDA receptor antagonists augment anticonvulsant effects of lithium chloride on pentylenetetrazole-induced clonic seizures in mice. Epilepsy Behav 2010, 18:171-178.
38. Shafaroodi H., Ghasemi M., Dehpour A.R. Elevation of pentylenetetrazole-induced seizure threshold in cholestatic mice: interaction between opioid and cannabinoid systems. J Gastroenterol Hepatol 2008, 23:e251-e257.
39. Löscher W., Hönack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs: III. Pentylenetetrazole seizure models. Epilepsy Res 1991, 8:171-189.
40. Niaki S.E., Shafaroodi H., Ghasemi M., Shakiba B., Fakhimi A., Dehpour A.R. Mouth breathing increases the pentylenetetrazole-induced seizure threshold in mice: a role for ATP-sensitive potassium channels. Epilepsy Behav 2008, 13:284-289.
41. Bahremand A., Shafaroodi H., Ghasemi M., Nasrabady S.E., Gholizadeh S., Dehpour A.R. The cannabinoid anticonvulsant effect on pentylenetetrazole-induced seizure is potentiated by ultra-low dose naltrexone in mice. Epilepsy Res 2008, 81:44-51.
42. Ghasemi M., Shafaroodi H., Karimollah A.R., et al. ATP-sensitive potassium channels contribute to the time-dependent alteration in the pentylenetetrazole-induced seizure threshold in diabetic mice. Seizure 2010, 19:53-58.
43. Honar H., Riazi K., Homayoun H., et al. Lithium inhibits the modulatory effects of morphine on susceptibility to pentylenetetrazole-induced clonic seizure in mice: involvement of a nitric oxide pathway. Brain Res 2004, 1029:48-55.
44. Mannino R.A., Wolf H.H. Opiate receptor phenomenon: proconvulsant action of morphine in the mouse. Life Sci 1974, 15:2089-2096.
45. Crain S.M., Shen K.F. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol Sci 1990, 11:77-81.
46. Kuriyama K., Yoneda Y. Morphine induced alterations of gamma-aminobutyric acid and taurine contents and l-glutamate decarboxylase activity in rat spinal cord and thalamus: possible correlates with analgesic action of morphine. Brain Res 1978, 148:163-179.
47. Moroni F., Cheney D.L., Peralta E., Costa E. Opiate receptor agonists as modulators of gamma-aminobutyric acid turnover in the nucleus caudatus, globus pallidus and substantia nigra of the rat. J Pharmacol Exp Ther 1978, 207:870-877.
48. Sagratella S., Massotti M. Convulsant and anticonvulsant effects of opioids: relationship to GABA-mediated transmission. Neuropharmacology 1982, 21:991-1000.
49. Bahremand A., Nasrabady S.E., Ziai P., et al. Involvement of nitric oxide-cGMP pathway in the anticonvulsant effects of lithium chloride on PTZ-induced seizure in mice. Epilepsy Res 2010, 89:295-302.
50. Roy U., Mukherjee B.P. Correlation of lithium effect on electroshock-induced seizure in rats with its concentration in brain and plasma. Arch Int Pharmacodyn Ther 1982, 255:81-88.
51. Schmidt J. Lithium suppresses seizure susceptibility in pentylenetetrazol-kindled rats. Biomed Biochim Acta 1986, 45:1167-1172.
52. Kadlimatti S.H., Joseph T. Influence of lithium on the anticonvulsant activity of carbamazepine. Indian J Physiol Pharmacol 1987, 31:35-41.
53. Post R.M., Weiss S.R., Pert A. Differential effects of carbamazepine and lithium on sensitization and kindling. Prog Neuropsychopharmacol Biol Psychiatry 1984, 8:425-434.
54. Clifford D.B., Podolsky A., Zorumski C.F. Acute effects of lithium on hippocampal kindled seizures. Epilepsia 1985, 26:689-692.
55. Tomkiewicz M., Steinberg H. Lithium treatment reduces morphine self-adminstration in addict rats. Nature 1974, 252:227-229.
56. Raffa R.B., Martinez R.P. Morphine antinociception is mediated through a LiCl-sensitive, IP3-restorable pathway. Eur J Pharmacol 1992, 215:357-358.
57. Raffa R.B., Martinez R.P., Renzi M.J., Codd E.E. LiCl uncouples signal transduction in morphine-induced supraspinal antinociception in mice. Gen Pharmacol 1995, 26:317-320.
58. Carroll B.J., Sharp P.T. Rubidium and lithium: opposite effects on amine-mediated excitement. Science 1971, 172:1355-1357.
59. Amir S., Simantov R. Chronic lithium administration alters the interaction between opiate antagonists and opiate receptors in vivo. Neuropharmacology 1981, 20:587-591.
60. You Z.D., Li J.H., Song C.Y., Lu C.L., He C. Oxytocin mediates the inhibitory action of acute lithium on the morphine dependence in rats. Neurosci Res 2001, 41:143-150.
61. Gambarana C., Mangiavacchi S., Masi F., et al. Long-term lithium administration abolishes the resistance to stress in rats sensitized to morphine. Brain Res 2000, 877:218-225.
62. Spasov A.A., Iezhitsa I.N., Kharitonova M.V., Kravchenko M.S. Effect of magnesium chloride and magnesium l-aspartate on seizure threshold in rats under conditions of dietary magnesium deficiency. Bull Exp Biol Med 2007, 144:214-216.
63. Chuang D.M. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?. Crit Rev Neurobiol 2004, 16:83-90.
64. Basselin M., Chang L., Bell J.M., Rapoport S.I. Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology 2006, 31:1659-1674.
65. 2+ of NMDA responses in spinal cord neurones. Nature 1984, 309:261-263.
66. Begon S., Pickering G., Eschalier A., Dubray C. Magnesium and MK-801 have a similar effect in two experimental models of neuropathic pain. Brain Res 2000, 887:436-439.
67. Fawcett W.J., Haxby E.J., Male D.A. Magnesium: physiology and pharmacology. Br J Anaesth 1999, 83:302-320.
68. 4) reduces experimental osteoarthritis and nociception: association with attenuation of N-methyl-d-aspartate (NMDA) receptor subunit 1 phosphorylation and apoptosis in rat chondrocytes. Osteoarthritis Cartilage 2009, 17:1485-1493.
69. Poleszak E., Wlaz P., Kedzierska E., et al. NMDA/glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice. Pharmacol Biochem Behav 2007, 88:158-164.
70. Poleszak E., Wlaz P., Wrobel A., Fidecka S., Nowak G. NMDA/glutamate mechanism of magnesium-induced anxiolytic-like behavior in mice. Pharmacol Rep 2008, 60:655-663.
71. Ahmed M.M., Arif M., Chikuma T., Kato T. Pentylenetetrazol-induced seizures affect the levels of prolyl oligopeptidase, thimet oligopeptidase and glial proteins in rat brain regions, and attenuation by MK-801 pretreatment. Neurochem Int 2005, 47:248-259.
72. Croucher M.J., Collins J.F., Meldrum B.S. Anticonvulsant action of excitatory amino acid antagonists. Science 1982, 216:899-901.
73. Gmiro V.E., Serdyuk S.E. Combined blockade of AMPA and NMDA receptors in the brain of rats prevents pentylenetetrazole-induced clonic and tonic-clonic seizures without ataxia. Bull Exp Biol Med 2008, 145:728-730.
74. Mares P., Mikulecka A. Different effects of two N-methyl-d-aspartate receptor antagonists on seizures, spontaneous behavior, and motor performance in immature rats. Epilepsy Behav 2009, 14:32-39.
75. Velisek L., Veliskova J., Ptachewich Y., Shinnar S., Moshe S.L. Effects of MK-801 and phenytoin on flurothyl-induced seizures during development. Epilepsia 1995, 36:179-185.
76. Jones A.W., Croucher M.J., Meldrum B.S., Watkins J.C. Suppression of audiogenic seizures in DBA/2 mice by two new dipeptide NMDA receptor antagonists. Neurosci Lett 1984, 45:157-161.
77. Hironaka N., Niki H. Effects of N-methyl-d-aspartate receptor subunit antagonists on regulation of susceptibility to audiogenic seizures in rats. Neurosci Lett 2000, 288:139-142.
78. Borris D.J., Bertram E.H., Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res 2000, 42:117-122.
79. Dodson W.E. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia 1993, 34(Suppl. 7):S18-S24.
80. Krystal A.D., Weiner R.D., Dean M.D., et al. Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. J Neuropsychiatry Clin Neurosci 2003, 15:27-34.
81. Kleckner N.W., Glazewski J.C., Chen C.C., Moscrip T.D. Subtype-selective antagonism of N-methyl-d-aspartate receptors by felbamate: insights into the mechanism of action. J Pharmacol Exp Ther 1999, 289:886-894.
82. Sachdeo R., Kramer L.D., Rosenberg A., Sachdeo S. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992, 32:386-392.
83. Leppik I.E., Dreifuss F.E., Pledger G.W., et al. Felbamate for partial seizures: results of a controlled clinical trial. Neurology 1991, 41:1785-1789.
84. Faught E., Sachdeo R.C., Remler M.P., et al. Felbamate monotherapy for partial-onset seizures: an active-control trial. Neurology 1993, 43:688-692.
85. Ghasemi M., Shafaroodi H., Nazarbeiki S., et al. Inhibition of NMDA receptor/NO signaling blocked tolerance to the anticonvulsant effect of morphine on pentylenetetrazole-induced seizures in mice. Epilepsy Res 2010, 91:39-48.